These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25712934)

  • 41. Management of phosphorus load in CKD patients.
    Taketani Y; Koiwa F; Yokoyama K
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Kidney and bone update : the 5-year history and future of CKD-MBD. Disorders of musculoskeletal system in CKD ; bone fracture and periarticular calcification].
    Yamada S; Taniguchi M
    Clin Calcium; 2012 Jul; 22(7):1000-7. PubMed ID: 22750932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
    Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities.
    Himmelsbach A; Ciliox C; Goettsch C
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32183352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular calcification in nondialyzed patients with chronic kidney disease.
    Qunibi WY
    Semin Dial; 2007; 20(2):134-8. PubMed ID: 17374087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment.
    Tomiyama C; Carvalho AB; Higa A; Jorgetti V; Draibe SA; Canziani ME
    J Bone Miner Res; 2010 Mar; 25(3):499-504. PubMed ID: 19594321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.
    Hanudel MR; Salusky IB
    Curr Osteoporos Rep; 2017 Jun; 15(3):198-206. PubMed ID: 28455644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphorus and other aspects of CKD-MBD in the conservative management of chronic kidney disease.
    Shah A
    Panminerva Med; 2017 Jun; 59(2):124-132. PubMed ID: 28290186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD.
    Jorgetti V; dos Reis LM; Ott SM
    Kidney Int; 2014 Jun; 85(6):1283-9. PubMed ID: 24352156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
    Diniz H; Frazão JM
    Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Women and CKD-mineral and bone disorder.
    Ho LT; Sprague SM
    Adv Chronic Kidney Dis; 2013 Sep; 20(5):423-6. PubMed ID: 23978548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease.
    Staude H; Jeske S; Schmitz K; Warncke G; Fischer DC
    Kidney Blood Press Res; 2013; 37(1):68-83. PubMed ID: 23548827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Recommendations for mineral and bone disorder in chronic kidney disease].
    Staszków M; Przedlacki J
    Wiad Lek; 2014; 67(3):422-5. PubMed ID: 25782204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Can cardiovascular calcifications be prevented in chronic kidney disease?].
    Coen G; Manni M; Mantella D; Splendiani G
    G Ital Nefrol; 2006; 23 Suppl 34():S21-5. PubMed ID: 16633990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.